 1. Patients with any stage epithelial ovarian cancer, including cancers arising from the fallopian tube and primary peritoneal cancer, or patients with other gynecologic malignancy any stage, who are chemotherapy-naïve, and scheduled to undergo at least 6 cycles of intravenous platinumtaxane-based chemotherapy. 